Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 52, Issue 1, 2009, Pages 44-50

  Park, Julie R ^a,h   Villablanca, Judith G ^b   London, Wendy B ^c   Gerbing, Robert B ^d   Haas Kogan, Daphne ^e   Adkins, E Stanton ^f   Attiyeh, Edward F ^g   Maris, John M ^g   Seeger, Robert C ^b   Reynolds, C Patrick ^b   Matthay, Katherine K ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f South Carolina Cancer Center   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Hematopoietic stem cell transplant; Neuroblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; ISOTRETINOIN; MELPHALAN; MESNA; CYCLOPHOSPHAMIDE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW RESCUE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; EVENT FREE SURVIVAL; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INFANT; METHODOLOGY; MORTALITY; PHASE 3 CLINICAL TRIAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL; TREATMENT OUTCOME;

BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HUMANS; INFANT; ISOTRETINOIN; NEUROBLASTOMA; RADIOTHERAPY; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 58149391059     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21784     Document Type: Article

References (16)

1. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage 3 neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J Clin Oncol 1998;16:1256-1264.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. N Engl J Med 1999;341:1165-1173.
3. Shimada H, Chatten J, Newton W, Jr., et al. Histophatologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglineuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416.
4. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
5. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-2253.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
7. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. JRSSA 1972;135:185-198.
8. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124.
9. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
10. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005;6:649-658.
11. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999;86:364-372.
12. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 2005;23:6466-6473.
13. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group study. J Clin Oncol 2005;23:6474-6480.
14. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-2279.
15. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study. J Clin Oncol 2000;18:1888-1899.
16. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-4669.